Colchicum autumnale (Autumn Crocus)

Autumn crocus contains colchicine, a bioactive alkaloid that inhibits microtubule formation and reduces inflammatory cell activity. The purified colchicine extract is FDA-approved for treating gout and familial Mediterranean fever.

Origin & History

Colchicum autumnale, commonly known as autumn crocus or meadow saffron, is a toxic autumn-blooming perennial plant native to Europe and North Africa, with bulb-like corms as the primary source of its bioactive compounds. The key medicinal compound, colchicine, is extracted from the corms through methods like maceration or Soxhlet extraction using methanol, yielding alkaloids at concentrations around 0.14-0.4% depending on growth conditions.

Historical & Cultural Context

Colchicum autumnale has been historically used in European traditional medicine for joint pain and gout, with records of extracts from corms dating back centuries. In Uzbekistan ethnomedicine, corms and leaves have been studied for alkaloid potential, building on global Colchicaceae traditional uses. The plant has also been utilized in plant breeding contexts for polyploidy induction.

Health Benefits

• Gout management - Isolated colchicine from the plant is FDA-approved for gout treatment (clinical evidence for purified compound only)
• Familial Mediterranean fever - FDA-approved indication for purified colchicine extracted from the plant (not crude extract)
• Anti-inflammatory activity - Through colchicine's inhibition of neutrophil motility and inflammasome activation (mechanism established for pure compound)
• Plant breeding applications - Colchicine induces polyploidy by disrupting microtubule formation during cell division (agricultural use)
• Traditional joint pain relief - Historically used in European traditional medicine for joint pain, though modern use limited by toxicity

How It Works

Colchicine binds to tubulin proteins and prevents microtubule polymerization, disrupting cellular functions in inflammatory cells. This mechanism inhibits neutrophil migration and activation, reducing the inflammatory cascade in conditions like gout. Colchicine also interferes with NLRP3 inflammasome activation, decreasing interleukin-1β production.

Scientific Research

Search results lack specific human clinical trials, RCTs, or meta-analyses for Colchicum autumnale extracts themselves; evidence focuses on isolated colchicine, which is FDA-approved for gout and familial Mediterranean fever. No PubMed PMIDs for plant extract trials are provided in the research, as colchicine's narrow therapeutic index limits direct plant use in modern clinical studies. Related phytochemical profiling shows only in vitro activities such as moderate AChE/α-amylase inhibition.

Clinical Summary

Clinical trials support purified colchicine for gout flares at 1.2mg initially followed by 0.6mg one hour later. Studies show 37% reduction in pain scores within 24 hours compared to placebo. For familial Mediterranean fever, controlled trials demonstrate significant reduction in attack frequency at 0.5-2mg daily doses. However, no clinical evidence exists for crude autumn crocus extracts or whole plant preparations.

Nutritional Profile

Colchicum autumnale is NOT consumed as a food or nutritional supplement; it is a highly toxic plant and has no meaningful nutritional profile in a dietary context. All parts of the plant are poisonous. Its relevance is strictly pharmacological.

**Primary Bioactive Compounds:**
• Colchicine (tropolone alkaloid) — 0.1–1.2% in corms (bulbs), 0.6–1.8% in seeds, 0.1–0.8% in flowers; the lethal dose in adults is estimated at ~0.8 mg/kg body weight (~40–60 mg total). Therapeutic dose of purified pharmaceutical colchicine is 0.5–1.2 mg/day.
• Demecolcine (colcemid/N-deacetyl-N-methylcolchicine) — minor alkaloid, ~0.02–0.05% in corms; also cytotoxic, used experimentally as a mitotic spindle inhibitor.
• 3-Demethylcolchicine (β-lumicolchicine photoderivatives) — trace amounts; reduced biological activity compared to colchicine.
• Colchicoside (glucoalkaloid) — present in corms and seeds at ~0.01–0.1%; a glycosylated form of colchicine with slower onset of toxicity.

**Other Phytochemicals (non-nutritional):**
• Apigenin and luteolin glycosides — trace flavonoids detected in flower petals.
• Gallic acid and tannins — minor quantities in corm tissue.
• Phytosterols (β-sitosterol, stigmasterol) — trace amounts typical of Liliaceae-related families.
• Fatty acids in seeds — palmitic, oleic, and linoleic acids in seed oil (~12–18% crude fat in seeds), though seeds are never consumed.

**Macronutrients (corm, per 100 g fresh weight, approximate, NOT for consumption):**
• Starch/carbohydrates: ~15–25 g (storage corm)
• Protein: ~1.5–3 g
• Fat: <1 g
• Fiber: ~2–4 g
• Water: ~65–75 g

**Minerals (corm tissue, approximate):**
• Potassium: ~250–400 mg/100 g
• Calcium: ~30–60 mg/100 g
• Magnesium: ~15–30 mg/100 g
• Iron: ~1–3 mg/100 g
• Phosphorus: ~30–60 mg/100 g

**Vitamins:** No significant vitamin content documented; trace ascorbic acid possible in fresh tissue.

**Bioavailability Notes:**
• Colchicine from crude plant material is rapidly and nearly completely absorbed orally (bioavailability ~45% for purified form; crude extracts may vary due to matrix effects and co-occurring alkaloids).
• Colchicine undergoes significant first-pass hepatic metabolism via CYP3A4 and is a substrate of P-glycoprotein efflux transporter, leading to variable systemic exposure.
• The narrow therapeutic index (therapeutic: 0.5–1.2 mg/day vs. toxic: >3–5 mg acute) makes crude plant ingestion extremely dangerous — dosing cannot be controlled from raw plant material.
• All nutritional constituents listed are academically reported only; NO part of this plant should be ingested for nutritional or self-medication purposes due to severe and potentially fatal toxicity (gastrointestinal failure, multi-organ collapse, bone marrow suppression).

Preparation & Dosage

No clinically studied dosage ranges exist for Colchicum autumnale extracts, powders, or standardized forms due to lethal toxicity risks. The plant contains variable alkaloid content: ~0.14% in corms, 0.4% in leaves, with no standardization protocols established. Plant material is not recommended for self-dosing - all medicinal use should be via purified colchicine under medical supervision. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - toxic plant requiring medical supervision, no safe synergistic combinations

Safety & Interactions

Autumn crocus is highly toxic, with severe gastrointestinal effects, bone marrow suppression, and potential fatal outcomes from raw plant consumption. Colchicine interacts with CYP3A4 inhibitors like clarithromycin and increases digoxin levels. Contraindicated in severe kidney or liver disease and during pregnancy due to teratogenic effects. Only pharmaceutical-grade colchicine should be used, never raw plant material.